Click here to receive MS news via e-mail
Walking ability, as reported by patients, significantly improved
LONDON -- The only drug approved to improve mobility in multiple sclerosis (MS) patients -- dalfampridine (Ampyra) -- has long been plagued by doubts about its efficacy, but a randomized trial reported here suggests that the drug genuinely does produce clinically significant improvements in walking ability.
In the 633-patient, 24-week study, 43.2% of those receiving dalfampridine (known simply as fampridine outside the U.S.) showed improvement of at least 8 points on the 12-point, patient-reported MS Walking Scale (MSWS), compared with 33.6% of the placebo group (P=0.006), reported Jeremy Hobart, BSc, PhD, of Plymouth University in England.
MS Views and News
Providing educational information, resources and services for those affected by MS